Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.
By P. Schuetz, M. Christ-Crain, R. Thomann, C. Falconnier, M. Wolbers, I. Widmer, Stefanie Neidert, Thomas Fricker, C. Blum, U. Schild and 9 more. Journal of the American Medical Association (JAMA), 2009
958 citations recorded by the source corpus.
Subfields: Applied Microbiology and Biotechnology, Critical Care and Intensive Care Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/f417e16927f0bfcfb8f43a7231d4d5cba383adfe
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Bjarnsholt
- Niels Høiby
- C. Moser
- G. Donelli
- D. Lebeaux
- L. Hall-Stoodley
- G. Bassi
- T. Coenye
Citations in the corpus
- ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. (2015, background): “The non-specific inflammatory markers (C-reactive protein, procalcitonin, erythrocyte sedimentation rate, white blood cells), or various cytokines cannot distinguish between infections caused by planktonic cells and biofilm infections (DIII) [108,109].”
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. (2017, background): “One review reported that antibiotics reduce the risk of shortterm mortality by 77%, treatment failure by 53% and sputum purulence by 44%(275) Procalcitonin-guided antibiotic treatment may reduce antibiotic exposure and side effects with the same clinical efficacy.(276,277) A study in patients with e”